Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study

Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study Publisher Pubmed

Hosen MI^{1, 2} ; Sheikh M^{1, 3} ; Zvereva M^{1, 4} ; Scelo G¹ ; Forey N¹ ; Durand G¹ ; Voegele C¹ ; Poustchi H⁵ ; Khoshnia M^{5, 6} ; Roshandel G⁶ ; Sotoudeh M³ ; Nikmanesh A³ ; Etemadi A^{5, 7} ; Avogbe PH¹ Show All Authors

Hosen MI^{1, 2}
Sheikh M^{1, 3}
Zvereva M^{1, 4}
Scelo G¹
Forey N¹
Durand G¹
Voegele C¹
Poustchi H⁵
Khoshnia M^{5, 6}
Roshandel G⁶
Sotoudeh M³
Nikmanesh A³
Etemadi A^{5, 7}
Avogbe PH¹
Chopard P¹
Delhomme TM¹
Foll M¹
Manel A⁸
Vian E⁸
Weiderpass E¹
Kamangar F⁹
Boffetta P^{10, 11}
Pharaoh PD¹²
Dawsey SM⁷
Abnet CC⁷
Brennan P¹
Mckay J¹
Malekzadeh R^{3, 5}
Calvezkelm FL¹

Show Affiliations

1. International Agency for Research on Cancer (IARC), Lyon, France
2. Department of Biochemistry and Molecular Biology, University of Dhaka, Dhaka, Bangladesh
3. Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russian Federation
5. Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
6. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran
7. Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States
8. Protestant Clinic of Lyon, Urology department, Lyon, France
9. Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, United States
10. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
11. Department of Medical and Surgical Sciences, University of Bologna, Italy
12. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

Source: EBioMedicine Published:2020

Abstract

Background: Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may provide a valuable opportunity for screening and management. Telomerase reverse transcriptase (TERT) promoter mutations detectable in urine have emerged as promising BC biomarkers. Methods: We performed a nested case-control study within the population-based prospective Golestan Cohort Study (50,045 participants, followed up to 14 years) and assessed TERT promoter mutations in baseline urine samples from 38 asymptomatic individuals who subsequently developed primary BC and 152 matched controls using a Next-Generation Sequencing-based single-plex assay (UroMuTERT) and droplet digital PCR assays. Findings: Results were obtained for 30 cases and 101 controls. TERT promoter mutations were detected in 14 pre-clinical cases (sensitivity 46·67%) and none of the controls (specificity 100·00%). At an estimated BC cumulative incidence of 0·09% in the cohort, the positive and negative predictive values were 100·00% and 99·95% respectively. The mutant allelic fractions decreased with the time interval from urine collection until BC diagnosis (p = 0·033) but the mutations were detectable up to 10 years prior to clinical diagnosis. Interpretation: Our results provide the first evidence from a population-based prospective cohort study of the potential of urinary TERT promoter mutations as promising non-invasive biomarkers for early detection of BC. Further studies should validate this finding and assess their clinical utility in other longitudinal cohorts. Funding: French Cancer League, World Cancer Research Fund International, Cancer Research UK, Tehran University of Medical Sciences, the International Agency for Research on Cancer, and the U.S. National Cancer Institute. © 2020

Related Docs

View other Related Docs

1. Tert Promoter Mutations As Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region, International Journal of Molecular Sciences (2022)

2. Liquid Biopsy in Bladder Tumors, Liquid Biopsy in Urogenital Cancers and its Clinical Utility (2022)

3. Household Fuel Use and the Risk of Gastrointestinal Cancers: The Golestan Cohort Study, Environmental Health Perspectives (2020)

4. Development of a Digestive Cancer Risk Score Based on Nutritional Predictors: A Risk Prediction Model in the Golestan Cohort Study, Nutrition and Cancer (2025)

5. Estimating the Prevalen Developing Country, Medical Journal of the Islamic Republic of Iran (2022)

6. Increased Expression of Urinary Exosomal Lncrna Tug-1 in Early Bladder Cancer, Gene Reports (2021)

7. Building a Cancer Biobank in a Low-Resource Setting in Northern Iran: The Golestan Cancer Biobank, Archives of Iranian Medicine (2021)

8. Trends in the Incidence of Stomach Cancer in Golestan Province, a High-Risk Area in Northern Iran, 2004-2016, Archives of Iranian Medicine (2020)

Experts (# of related papers)

View all Related Experts

Hossein Poustchi (4)

Reza Malekzadeh (3)

Style	Citing Format
MLA	Hosen MI, et al.. "Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study." EBioMedicine, vol. 53, no. , 2020, pp. -.
APA	Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, Voegele C, Poustchi H, Khoshnia M, Roshandel G, Sotoudeh M, Nikmanesh A, Etemadi A, Avogbe PH, Chopard P, Delhomme TM, Foll M, Manel A, Vian E, ... Calvezkelm FL (2020). Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study. EBioMedicine, 53(), -.
Chicago	Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, Voegele C, et al.. "Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study." EBioMedicine 53, no. (2020): -.
Harvard	Hosen MI et al. (2020) 'Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study', EBioMedicine, 53(), pp. -.
Vancouver	Hosen MI, Sheikh M, Zvereva M, Scelo G, Forey N, Durand G, et al.. Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study. EBioMedicine. 2020;53():-.
BibTex	@article{ author = {Hosen MI and Sheikh M and Zvereva M and Scelo G and Forey N and Durand G and Voegele C and Poustchi H and Khoshnia M and Roshandel G and Sotoudeh M and Nikmanesh A and Etemadi A and Avogbe PH and Chopard P and Delhomme TM and Foll M and Manel A and Vian E and Weiderpass E and Kamangar F and Boffetta P and Pharaoh PD and Dawsey SM and Abnet CC and Brennan P and Mckay J and Malekzadeh R and Calvezkelm FL}, title = {Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study}, journal = {EBioMedicine}, volume = {53}, number = {}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Hosen MI AU - Sheikh M AU - Zvereva M AU - Scelo G AU - Forey N AU - Durand G AU - Voegele C AU - Poustchi H AU - Khoshnia M AU - Roshandel G AU - Sotoudeh M AU - Nikmanesh A AU - Etemadi A AU - Avogbe PH AU - Chopard P AU - Delhomme TM AU - Foll M AU - Manel A AU - Vian E AU - Weiderpass E AU - Kamangar F AU - Boffetta P AU - Pharaoh PD AU - Dawsey SM AU - Abnet CC AU - Brennan P AU - Mckay J AU - Malekzadeh R AU - Calvezkelm FL TI - Urinary Tert Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence From the Golestan Cohort Study JO - EBioMedicine VL - 53 IS - SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract